Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry

This study showed that the safety profile of adjuvant atezolizumab outside of a clinical trial context was comparable to the IMPower-010 study, highlighting the value of the Italian ATLAS registry as source of real-word evidence to optimize the clinical management of NSCLC patients.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2025-12-23
DOI
https://doi.org/10.1093/oncolo/oyaf428
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry

Gabriele Minuti, Lorenzo Calvetti, Luca Toschi, Ilaria Attili et al.
The Oncologist
Lung Cancer Treatments and Mutations
article

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry

Gabriele Minuti, Lorenzo Calvetti, Luca Toschi, Ilaria Attili, V. Scotti, K. Andrikou, Rita Chiari, Gloria Borra, Stefania Gori, Teresa Del Giudice, Luca Tondulli, Giulia La Cava, Carminia Maria Della Corte, Alessandra Bulotta, Fabrizio Tabbò, Chiara Bennati, Daniele Pozzessere, Adolfo Favaretto, Giuseppe Viscardi, A. Russo, Elisa Roca, Maria Lucia Reale, F. Mazzoni, Brigida Stanzione, Daniele Pignataro, Sabrina Mariotti, Lorenzo Belluomini, Anna Bettini, E. Bria, Carlo Genova, Giulia Pasello, Anna Maria Carta, Alberto Pavan, Concetta Sergi, Umberto Malapelle, Alain Jonathan Gelibter, Francesco Passiglia, Elio Gregory Pizzutillo, Salvatore Grisanti, Maria Pagano, Domenico Galetta, Giuseppe Lo Russo, Tiziana Vavala’, Chiara Catania, Silvia Novello, Alessandra Dodi
article en

Abstract

This study showed that the safety profile of adjuvant atezolizumab outside of a clinical trial context was comparable to the IMPower-010 study, highlighting the value of the Italian ATLAS registry as source of real-word evidence to optimize the clinical management of NSCLC patients.

The OncologistVol. 31(2)
University of Verona (IT), Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), Humanitas University (IT), University of Padua (IT), Università Campus Bio-Medico (IT), Agostino Gemelli University Polyclinic (IT), Brescia University (US), University of Catania (IT), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Ospedale di Bolzano (IT), Dulbecco Telethon Institute (IT), Ospedale "Santa Maria delle Croci" di Ravenna (IT), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Ospedale Sacro Cuore Don Calabria (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Ospedale Garibaldi (IT), Ospedale Papa Giovanni XXIII (IT), Casa di Cura Villa Garda (IT), Istituto Oncologico Veneto (IT), Azienda Sanitaria Locale di Asti (IT), University Hospitals Parma Medical Center (US), Azienda Ospedaliero-Universitaria Careggi (IT), Ospedale Santa Maria (IT), Azienda Ospedaliero Universitaria Maggiore della Carita (IT), Instituto de Pesca (BR), Azienda Ospedaliera S.Maria (IT), Humanitas Gavazzeni (IT), University of Campania "Luigi Vanvitelli" (IT), Centro di Riferimento Oncologico (IT), Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli (IT), Istituto Tumori Bari (IT), IRCCS Ospedale San Raffaele (IT), National Cancer Institute (MY), Policlinico Tor Vergata (IT), Ospedale Monaldi (IT), Azienda Ospedaliera Ospedale Maggiore (IT), Ca' Foncello Hospital (IT), Ospedale Policlinico San Martino (IT), Ospedale San Bortolo (IT), Ospedale Vito Fazzi (IT), Ospedale San Luigi Gonzaga (IT), Azienda Usl Toscana Centro (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Ospedale Civile di Venezia (IT), Ospedale San Pietro Fatebenefratelli (IT), Azienda Ospedaliera G. Brotzu (IT), European Institute of Oncology (IT), University of Naples Federico II (IT), University of Brescia (IT), Sapienza University of Rome (IT)
Good health and well-being
Openalex Percentile: Top 28%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.